Cellix Bio Pharma, a global contract research organization (CRO), transforms today’s healthcare challenges into tomorrow’s solutions. Cellix Bio Pharma is an experienced CRO focused on development of pharmaceutical formulations. Cellix Bio Pharma focuses to combine the AI computational power to the chemical and biological space in order to streamline drug discovery, design, development, and optimization that can expedite drug development.
Hyderabad, India, April 10, 2020 --(PR.com)-- Cellix Bio Pharma initiates the acquisition of Avaca Pharma, a formulation development CRO. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities.
The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and development capabilities, this expansion uniquely position Cellix Bio Pharma as a leading provider of integrated R&D services across both large and small molecule platforms and provides a base for further expansion.
With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions to their clients.
More from miscw.com
MUFG Bank, Ltd. Announces Consolidated Summary Report of Mitsubishi UFJ Financial Group, Inc. Under Japanese GAAP for the Three Months Ended June 30, 2020- Global Stem Cells Market is estimated to account for US$ 18,289.9 Mn by end of 2027, Says Coherent Market Insights (CMI)
World-Class Design Meets Cutting-Edge Innovation in TUMI�s Spring 2023 Collection- CGTN:�Xi Jinping Reviews Poverty Relief Progress in Hunan as China’s War on Poverty Nears End
